T he cancer stem-cell model provides one explanation for the phenotypic and functional heterogeneity among cancer cells in some tumours [1] [2] [3] [4] [5] . The model posits that some cancers are organized into a hierarchy of subpopulations of tumorigenic cancer stem cells and their non-tumorigenic progeny. In these cases, cancer stem cells are thought to drive tumour growth and disease progression, perhaps through therapy resistance [6] [7] [8] and metastasis 9, 10 . However, difficulty replicating solid-cancer stem-cell markers, variability from patient to patient and variation in results from different xenograft models have meant that it is unclear what fraction of cancers follow this model -the majority or only a minority 11 ? Even in cancers that clearly contain a hierarchy of tumorigenic and non-tumorigenic cells, this hierarchy must coexist with other sources of heterogeneity, including clonal evolution 12 (see the Review by Swanton and colleagues on page 338), heterogeneity in the micro-environment 13, 14 (see the Review by Junttila and de Sauvage on page 346) and reversible changes in cancer-cell properties that can occur independently of hierarchical organization [15] [16] [17] [18] . In these circumstances it is not necessarily clear which phenotypic and functional differences among cells arise from which sources of heterogeneity. To what extent do metastasis, therapy resistance and disease progression reflect the intrinsic properties of cancer stem cells as opposed to genetic evolution or other sources of heterogeneity? Integration of results from multiple experimental approaches will be necessary to distinguish the relative contributions of these sources of heterogeneity to disease progression.
New experimental approaches have provided perspective and insight into this question. Genetic approaches to fate map the contributions of cancer cells to tumour growth in mice have provided evidence to support the cancer stem-cell model in some contexts, and evidence against the model in others [19] [20] [21] [22] [23] . Transplantation assays evaluate the potential of cancer cells to form tumours, rather than their actual fate in the native tumour, and so fate mapping complements what we have learned from transplantation assays (Fig. 1) . High-coverage sequencing of human tumours has also provided insight into genetic heterogeneity within tumours and the cells that are responsible for relapse after therapy [24] [25] [26] [27] [28] . In this Review, we evaluate the implications of these new data for the cancer stem-cell model and the extent to which this model accounts for clinically important forms of heterogeneity in cancer.
Tests for tumorigenic potential
Central to the cancer stem-cell model is the idea that tumour growth and disease progression are driven by minority populations of tumorigenic cells, and that most other cancer cells have little or no capacity to contribute to tumour growth. This means that therapeutic strategies should focus particularly on killing tumorigenic cells. In experiments, the cancer stem-cell model has mainly been tested using transplantation assays, which test the potential of a cancer cell to form a tumour. These assays have demonstrated the existence of phenotypically distinct subpopulations of tumorigenic and non-tumorigenic cells in a number of human cancers, including acute myeloid leukaemia (AML) 29, 30 , chronic myeloid leukaemia (CML) 31 , breast cancer 32 , glioblastoma 6, 33 , colorectal cancer [34] [35] [36] , pancreatic cancer 37 and ovarian cancer [38] [39] [40] . In these studies, the cells that formed tumours were rare. Nonetheless, in principle, tumorigenic cells could be common in some cancers that are hierarchically organized consistent with the cancer stem-cell model 41 .
Tumorigenic potential can only be tested in a permissive environment. A persistent concern is that there could be cancer cells that have the potential to contribute to tumour growth and disease progression in patients but do not have the opportunity to exhibit this potential in certain transplantation assays. A transplantation assay might underestimate the frequency of cancer cells with tumorigenic potential for many reasons. Human cells must be transplanted into highly immunocompromised mice to escape the powerful xenogeneic immune response that kills human cells in mice. Although a succession of increasingly immunocompromised mice have been used to assay the tumorigenic potential of human cancer cells, from nude to severe combined immunodeficient (SCID) to non-obese diabetic SCID (NOD/SCID) to NOD/ SCID IL-2Rγ-null mice (NSG), all of these mice retain some xenogeneic immune barrier 42 . There is no opportunity to test whether human cells have tumorigenic potential if they are killed by a xenogeneic immune response. The frequencies of human AML cells 30, 43 , acute lymphoblastic leukaemia (ALL) cells 44, 45 , melanoma cells 46 and lung cancer cells 47 with leukaemogenic or tumorigenic activity are much higher in more highly immunocompromised mice.
Other mechanisms also contribute to an underestimation of tumorigenic potential. Many mouse malignant peripheral nerve sheath tumour (MPNST) cells have tumorigenic potential, but cells of one genotype depend on exogenous molecules of the protein laminin to form tumours, whereas cells of another genotype express laminin cellautonomously 48 . This raises the arresting possibility that tumours from different patients might require different assay conditions to determine their full spectrum of tumorigenic cells. In other cases, key adhesion molecules or growth factors are required for cells to exhibit clonogenic activity but are not available to human cells in mouse tissues because of the inability of mouse ligands to bind human receptors 49 . Xenotransplanted tumours can also lack the architecture and stroma of tumours growing in native sites 50 . Many variables could influence the permissiveness of the environment for tumorigenesis, including uncharacterized factors that have not yet been taken into account in assays.
Given these concerns about xenotransplantation, it is reassuring that syngeneic transplantation of mouse cancer cells has also supported the cancer stem-cell model. Studies of cells from mouse germ-cell lineage cancers 51 , AML 52, 53 , chronic myelomonocytic leukaemia (CMML) 8 , CML 54 , breast cancer 55, 56 and medulloblastoma 57, 58 have all been consistent with the cancer stem-cell model. Many of these studies demonstrated that some fractions of cancer cells are enriched for tumorigenic activity even when there is no xenogeneic barrier to engraftment. Therefore, the cancer stem-cell model cannot be entirely an artefact of xenotransplantation.
Improvements to transplantation assay conditions have revealed that some cancers have common leukaemogenic or tumorigenic cells (some AMLs 59 For all of the reasons described, it will be crucial to continue to optimize transplantation assays to estimate as accurately as possible the spectrum of cancer cells that retain the potential to contribute to tumour growth. This will require systematically testing variations in xenotransplantation assay conditions, including the addition of variables such as human cytokines 63 that might influence human-cell engraftment 64 . Many researchers continue to transplant human cancers into heterotopic sites in mice without a careful comparison of the consequences of heterotopic compared with orthotopic engraftment. It will not be surprising if we are continuing to vastly underestimate the frequency of cells that can contribute to disease progression in some human cancers despite the advances made in xenotransplantation assays over the past few years.
Tests for hierarchical organization
Beyond showing that a cancer has tumorigenic and non-tumorigenic cells, the other criterion that must be satisfied according to the cancer stem-cell model is that the tumorigenic cells give rise to nontumorigenic progeny. Without demonstrating a lineage relationship, 57 . These findings are the basis for the idea that cancer stem cells form heterogeneous tumours by undergoing epigenetic changes, akin to the differentiation of normal stem cells.
However, for some cancers there is compelling evidence against the stem-cell model. Tumorigenic cells are common and phenotypically diverse in stage III and IV human melanomas 15, 46 . One study 66 suggested that only CD271 + melanoma cells can form tumours in immunocompromised mice. Another study 67 reported that CD271 − melanoma cells can form tumours in NSG mice, but that they cannot form CD271 + progeny or tumours in NOD/SCID mice. Our work suggests that both CD271 − and CD271
+ melanoma cells readily form tumours in both NOD/SCID and NSG mice, and that CD271 is expressed heterogeneously in these tumours 15, 46 . In an attempt to resolve the inconsistencies, we have compared the tumorigenic capacity of CD271 + and CD271 − melanoma cells isolated from multiple patients using our dissociation protocol 15, 46 , as well as the dissociation protocols described by Civenni et al. 67 and Boiko et al. 66 . Irrespective of which dissociation protocol we used, whether or not we injected the cells with Matrigel, or whether we transplanted into NOD/SCID or NSG mice, both CD271 + and CD271 − melanoma cells readily formed tumours and all the tumours were heterogeneous for CD271 (S.J.M., unpublished observations).We were unable to detect any fraction of melanoma cells that lacks tumorigenic potential when we tested over 20 heterogeneously expressed markers in tumours obtained from many patients 15, 46 . Difficulty in reproducing cancer stem-cell markers has been a common problem in solid-cancer studies. For example, CD133 seemed to robustly distinguish tumorigenic from non-tumorigenic brain tumour cells in early studies 6, 33 , but a series of subsequent studies [68] [69] [70] [71] found tumorigenic cells in both CD133 + and CD133 − fractions. Because the existence of markers that can distinguish tumorigenic from non-tumorigenic cancer cells is the experimental basis for the conclusion that these cancers follow the stem-cell model, the inability to widely confirm many solid-cancer stem-cell markers undermines the evidence supporting the model.
A related problem is that cancer stem-cell markers that were originally characterized in a limited number of tumours have often been assumed to be generalizable. Such markers have frequently been used in other tumours, or even in cell lines, without independent confirmation that the markers were informative in these contexts. For example, it was clear from an initial study of breast cancer stem cells that the CD44 
Variability among patients
One of the reasons for variability among studies is that markers expressed by tumorigenic cells differ among patients. Early studies on AML indicated that leukaemogenic cells were highly enriched among CD34 43, 65 . Many human AMLs with nucleophosmin mutations have leukaemogenic activity exclusively in the CD34 − fraction, but some have leukaemogenic activity in both CD34 − and CD34 + fractions 73 . This indicates that differences in mutations can cause differences in the phenotype of leukaemogenic cells among patients. The same is true for solid cancers. Sca1
+ cells have enriched tumorigenic activity in mouse lung adenocarcinomas with Kras and p53 mutations but not in tumours with only Kras mutations 74 . Differences among patients could also reflect differences in the cell of origin. For example, some medulloblastomas arise in the cerebellum from activation of the sonic hedgehog signalling pathway in granule neuron precursors and frequently have a poor prognosis 75 . Other medulloblastomas arise in the dorsal brainstem and are highly curable 75 . Similarly, neural progenitors from different regions of the central nervous system form different subtypes of ependymomas with different properties 76 . Both haematopoietic stem cells and restricted myeloid progenitors can serve as the cell of origin for AML 53, [77] [78] [79] , but the leukaemogenic cells have somewhat different properties in each case 80 . The distinct developmental origins of tumours, both with respect to regional identity and position in the normal tissue hierarchy, contribute to differences among patients in tumorigenic cell properties.
Tumorigenic cell phenotype can also change over time. In some ovarian cancers, only CD133 + cells have tumorigenic activity, whereas in others tumorigenic cells are found in the CD133 + and CD133 − fractions 40 .
Ovarian cancers with only CD133
+ tumorigenic cells sometimes give rise to CD133 − tumorigenic cells on serial transplantation in mice 40 .
If tumorigenic cell phenotypes commonly change on passaging of tumours, this could explain some of the inconsistencies observed among studies that use small numbers of tumours.
The frequency of tumorigenic cells in some cancers also varies widely among patients. Side-by-side studies of AMLs from different patients revealed frequencies of leukaemogenic cells in the CD34 + CD38
− cell fraction that varied by 1,000-fold 65 . B-lineage ALLs (B-ALLs) from different patients had frequencies of leukaemogenic cells that varied by 100-fold 44 
.
Ovarian cancers from different patients had tumorigenic cell frequencies that varied by almost 1,000-fold 40 . It remains uncertain to what extent this reflects biological variability in the frequency of cells that can contribute to tumour growth in patients as opposed to variability in the extent to which transplantation assays are permissive for tumorigenesis by cells of different genotypes. The variability in the frequency and identity of tumorigenic cells between patients shows that markers identified in one tumour cannot be assumed to distinguish cancer stem cells in other tumours or in other contexts.
A key question raised by the differences among patients is whether tumours of the same type differ in the extent to which they are hierarchically organized. For example, one possibility is that all breast cancers follow a stem-cell model even though existing markers do not distinguish tumorigenic from non-tumorigenic cells in some tumours. Another possibility is that only a subset of breast cancers follows the stem-cell model. Or that perhaps the hierarchy is steep in one subset of each cancer, with rare tumorigenic cells that give rise to abundant non-tumorigenic cells; and shallow in another subset of each cancer, with common tumorigenic cells that form a small number of non-tumorigenic cells (Fig. 2) . Until enough tumours are carefully studied to observe consistent patterns among patients with particular subtypes of disease, tumours will have to be tested individually to determine whether tumorigenic cells are common or rare and whether markers can distinguish tumorigenic from nontumorigenic cells.
Fate versus potential in tumours in vivo
Which cells actually contribute to the growth and progression of tumours in vivo? Most cancer stem-cell studies are designed to assess the identity of cancer cells with the potential to contribute to tumour growth. But we also want to know the identity of cells fated to contribute to the growth and progression of specific tumours ( Some cells that have the potential to drive tumour growth do not actually do so in the native tumour because they are not in a permissive environment or they are killed by immune cells or by therapy. In the native tumour, slowly proliferating clones might be at a competitive disadvantage to rapidly proliferating clones and therefore may not contribute much to tumour growth. However, these slowly proliferating clones might form tumours after transplantation. Environmental cues from stromal cells can restrict the growth of cancer cells in the native tumour environment 81 , but the absence of these cues may permit the same cells to form tumours after transplantation. In some circumstances, a high percentage of cells with tumorigenic potential could contribute to tumour growth (Fig. 1) . In other circumstances, there may only be a small percentage of cells with tumorigenic potential that actually contribute to tumour growth.
One context in which the fate of tumorigenic cells can be tracked is after xenotransplantation of human cancer cells. When primary human colorectal cancer cells were marked by lentiviral infection and the relative abundance of distinct clones was tracked as tumour cells were serially transplanted in mice 82 , individual clones differentially contributed to tumour growth over time. Some clones were always abundant, some were abundant then became rare and some were rare then became abundant. When human B-ALL cells from a single patient were transplanted at limiting and non-limiting cell doses, different dominant clones emerged in each recipient mouse 44 . Leukaemogenic clones thus do not contribute equally over time after transplantation.
Lineage tracing experiments in mouse models of benign tumours have tested whether many or few cells contribute to tumour growth 20, 21 . In a recent study, a conditional reporter allele was used to track the fate of individual tumour cells in mice bearing benign papillomas. By inducing recombination of the conditional reporter allele in a small percentage of papilloma cells, rare marked clones were tracked over time to assess their contribution to tumour growth. The mice were treated with low doses of the oestrogen inhibitor tamoxifen, allowing keratin14-CreER to permanently turn on a conditional reporter in a small percentage of papilloma cells 20 . The frequency of clones declined over time, with only 20% persisting after 7 weeks. Non-persisting clones seemed to be lost through terminal differentiation. The average number of cells in persisting clones increased over time: by 7 weeks the clones ranged from hundreds to thousands of cells. These observations demonstrate that only a minor subpopulation of tumour cells drives papilloma growth, although the rate at which these cells divide is increased relative to that observed in the normal epidermis 83 . Benign papillomas are therefore hierarchically organized, consistent with the stem-cell model, although this is perhaps not surprising for a benign tumour.
The same study also fate-mapped cells in tumours after they progressed to squamous cell carcinomas 20 . Cells in these tumours were more highly proliferative, more undifferentiated and formed larger clones compared with cells in benign papillomas. A high percentage of cells contributed sustainably to the growth of squamous cell carcinomas, which, in this study, had only a shallow hierarchy, with few nontumorigenic cells (Fig. 2) . Additional studies are required to determine whether there is any hierarchical organization among the persisting clones -perhaps some have more proliferative potential than others. Overall, the data suggest that as benign adenomas progress to carcinomas, the hierarchy becomes shallower and more cells can contribute to tumour growth.
Lgr5 expression marks normal stem cells in the intestinal crypt 84 the Lgr5 + and Lgr5 − cell fractions from adenomas of other genetic backgrounds will be required to assess what fraction of adenomas exhibits hierarchical organization. It will also be important to test whether adenomas that do exhibit hierarchical organization continue to do so after they progress to malignancies.
These lineage tracing experiments thus provide limited support for the cancer stem-cell model. Although the growth of benign skin papillomas was driven by a minor subpopulation of cells, a much larger fraction of cells contributed to the growth of squamous cell carcinomas 20 . A key question now is whether some of the persistent clones that exhibit an ongoing contribution to tumour growth might nonetheless have limited tumorigenic potential in transplantation assays. The data on intestinal adenomas also offer limited support for the cancer stem-cell model as both Lgr5 + and Lgr5 − cells have the ability to serve as the cell of origin and to propagate tumours on transplantation, at least in certain genetic backgrounds. Ultimately, it will be necessary to integrate the data from both transplantation studies and fate-mapping studies of significant numbers of human and mouse tumours to understand the biological diversity.
Fate testing through selective cell ablation
The selective ablation of genetically defined subsets of tumour cells is another approach to test which cells are fated to contribute to tumour growth or disease progression in the native tumour environment. A recent study 19 addressed the role of Nestin + cells in the maintenance of a mouse model of glioma by ablating these cells. The protein GFP and the herpes simplex virus thymidine kinase (HSV-TK) were expressed under the control of the nestin promoter such that HSV-TK + cells could be selectively killed on administration of the antiviral ganciclovir. Nestin-expressing GFP + glioma cells were relatively quiescent and represented a minority of cells in the gliomas. Administration of ganciclovir modestly extended the lifespan of mice, indicating that the Nestin + cells contribute to tumour growth. Importantly, when tumours were reduced in size by treatment with the chemotherapeutic temozolomide, pulse-chase experiments suggested that tumour regrowth originated from the Nestin + fraction of tumour cells. Coadministration of temozolomide and ganciclovir significantly slowed tumour regrowth; however, it was impossible to assess the long-term effects of eliminating Nestin + cells because mice independently developed lethal tumours unrelated to the original tumour. Consequently, it remains unclear whether Nestin + cells are exclusively responsible for driving tumour growth and recurrence after therapy or whether Nestin − cells also contribute. It would be particularly interesting to selectively ablate Nestin − cells to determine whether this also slows tumour growth and extends mouse lifespan. 
Reversible plasticity among cancer cells
Some cancer cells reversibly transition among states that differ in their competence to contribute to tumour growth 85 . For example, some cancer cells can reversibly transition between epithelial and mesenchymal states, and there is evidence that breast cancer cells in the mesenchymal state are more competent than those in the epithelial state to form tumours 9 . Melanoma cells reversibly turn on and off the histone demethylase JARID1B, and cells that express JARID1B are more competent to sustain tumour growth 16 than those that do not express JARID1B. Many other markers are reversibly turned on and off in lineages of melanoma cells in a manner that does not correlate with the ability to form a tumour 15, 17 . Exposure of glioma cells to perivascular nitric oxide reversibly promotes their ability to form tumours 13 . The evidence that some cancer cells can undergo reversible changes in their competence to form tumours offers an alternative explanation for the increased tumorigenic potential of subsets of cancer cells that is independent of the differentiation of cancer stem cells.
Drug resistance is also a plastic property of some cancer cells. Rare subpopulations in cancer cell lines that exhibit resistance to a variety of therapeutics reversibly form sensitive or resistant progeny depending on whether the cells are passaged with or without the therapeutic 18 . This raises the possibility of intrinsic therapy-resistance mechanisms that are not necessarily associated with a static hierarchy or an undifferentiated state.
It is crucial to distinguish models in which intrinsic differences in tumorigenic capacity reflect reversible changes in cell state from those in which intrinsic differences in tumorigenic capacity reflect irreversible differentiation, because these models make very different experimental and clinical predictions (Fig. 3) . If the heterogeneity within tumours reflects cells that reversibly and efficiently transition between tumorigenic and non-tumorigenic states 9,85 , it may not be possible to experimentally identify any population that lacks tumorigenic potential (Fig. 3b) . Furthermore, it would still be necessary to eliminate all cancer cells during therapy, as even the non-tumorigenic cells could drive disease recurrence by giving rise to tumorigenic cells (Fig. 3c) . By contrast, if heterogeneity reflects hierarchical organization in which cancer stem cells irreversibly differentiate into nontumorigenic cells, then therapies that eliminate cancer stem cells should be necessary and sufficient to cure disease (Fig. 3a, c) . This distinction is thus crucial to understand the underlying biology and to develop more effective therapies. Importantly, almost all of the existing evidence for reversible transitions between tumorigenic and non-tumorigenic states comes from studies of cells in culture, often cell lines, so it remains uncertain to what extent reversible transitions occur between tumorigenic and non-tumorigenic states in spontaneously arising cancers in vivo.
Genetic heterogeneity in tumours
The conclusion that cancer stem cells can recapitulate the heterogeneity of the tumours from which they are derived has consistently been based on analyses of small numbers of surface markers, calling into question the degree to which there is genetic heterogeneity within tumours that is not recapitulated after the transplantation of tumorigenic cells 86 . If genetic heterogeneity within tumours is low, then the differentiation of cancer stem cells into non-tumorigenic progeny could be the main driver of heterogeneity (Fig. 4) . Conversely, if genetic heterogeneity is extensive, every tumorigenic cell could form a genetically distinct tumour rather than recapitulating the tumour from which it is derived. In tumours with extensive genetic heterogeneity, phenotypic and functional differences among cells cannot be assumed to reflect the differentiation of cancer stem cells -the variations could reflect genetic differences.
With these possibilities as a backdrop, it is interesting to consider the implications of recent deep-sequencing studies. Deep sequencing has been used to examine the genetic heterogeneity in tumours, the subclonal composition of tumours and the evolutionary relationships of mutations during disease progression. Deep sequencing cannot directly test the cancer stem-cell model. However, the frequencies of allelic variants in bulk tumour cells can be used to quantify the relative contribution of different clones to tumours. Even neutral, passenger, mutations can be informative because by following the contribution of the cells bearing these mutations to tumour growth and disease progression we gain insight into the fates of individual cancer cells and their progeny. Data from AML 25, 87 , chronic lymphocytic leukaemia (CLL) 88 , breast cancer 27, 89, 90 , renal cell carcinoma 28,91 and pancreatic cancers [92] [93] [94] show surprisingly extensive genetic heterogeneity. Extensive genetic heterogeneity provides many opportunities for genetic changes to confer phenotypic and functional heterogeneity within tumours that is not addressed by the cancer stem-cell model (and that could complicate the testing of the model; Fig. 3 ). It has long been known that cancer cells undergo clonal evolution in which mutations occur stochastically in individual cancer cells and are then subject to positive or negative selection depending on whether they confer a competitive advantage or disadvantage 12, 95 . Cancer stem cells are no exception. Leukaemogenic ALL cells obtained from one patient exhibit genetic heterogeneity and undergo genetic changes over time when passaged in mice 24, 44 . Whether these ALLs follow the cancer stem-cell model is not clear, because leukaemogenic cells are common in some ALLs and it has proven difficult to identify any clear hierarchical organization 61, 96 . Human colorectal tumours have also been serially transplanted in mice, and their genetic heterogeneity assessed 82 . Only a small number of de novo genetic variants were detected in serially transplanted tumours compared with primary patient samples. Because there is compelling evidence that colorectal cancers are hierarchically organized into tumorigenic and nontumorigenic components [34] [35] [36] , these results show that genetic changes do occur in colon cancer stem cells, although the paucity of such changes raises the possibility that the rate of mutagenesis might be suppressed in those cells. There is no inherent inconsistency between the cancer stemcell model and the clonal evolution model 4 (Fig. 5) .
Therapy resistance
Tumorigenic cells in certain cancers are intrinsically resistant to certain therapies. For example, tumorigenic glioblastoma 6 and breast cancer 7 cells have been found to be enriched after irradiation of xenografts. If every tumorigenic cell carries a combination of common and unique (coloured stars) mutations, then none of these cells will recapitulate the genetic heterogeneity of the tumour from which they are derived -they will all give rise to genetically distinct tumours on transplantation. They still may give rise to hierarchically organized tumours with tumorigenic and non-tumorigenic components, as in the tumour of origin. Nonetheless, if the genetic heterogeneity involves mutations that influence cancer cell phenotype or function, the genetic heterogeneity will contribute to tumour heterogeneity through mechanisms independent of cancer stem cell differentiation.
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A similar enrichment of tumorigenic cells has been observed in cyclophosphamide-treated colorectal tumours 97 . Activation of ATMdependent DNA-damage repair in tumorigenic glioblastoma cells 6 and decreased reactive oxygen species in tumorigenic breast cancer cells 7 may explain the therapy resistance of these cells.
Although it has been suggested that cancer stem cells can be defined by therapy resistance, this is not true in any general sense. Differentiation therapies specifically target cancer stem cells by exploiting their capacity to differentiate. Acute promyelocytic leukaemia (APL) is treated with arsenic trioxide and trans-retinoic acid to induce terminal differentiation, growth arrest and apoptosis by clonogenic APL cells 98 . Mouse glioblastoma stem cells can be induced to differentiate into glia by treatment with the protein BMP4, reducing proliferation, tumour growth and tumorigenic cell frequency 99 . BMP4 also promotes glial differentiation by normal central nervous system stem cells 100 , suggesting that tumorigenic cancer cells sometimes inherit differentiation pathways from normal stem cells in the same tissue. Cis-retinoic acid improves survival in highrisk neuroblastoma patients 101, 102 by inducing the differentiation of undifferentiated neuroblastoma cells. Thus, tumorigenic cells are more sensitive to some therapies and less sensitive to others compared with non-tumorigenic cells. Genetic changes clearly confer therapy resistance in some circumstances 103 . Sequential genetic analysis of cancers before therapy and after relapse have been consistent with this. In ALL 24,26 , AML 25 and CLL 88, 104 , minor subclones before therapy often become dominant after therapy. If the inherent therapy resistance of cancer stem cells were the main determinant of survival during therapy, then dominant clones before therapy would probably remain dominant after therapy. The observation that therapy selects for minor subclones suggests that survival is stochastic (many cells have a similarly low probability of surviving), non-cell-autonomously determined or determined by genetic differences among subclones.
When the dominant pretherapy clone remains dominant after relapse, the dominant clone often gains de novo mutations 25,26,88 . Relapse-specific mutations can confer therapy resistance. For example, recurrent relapse-specific mutations have been identified in the gene NT5C2 in 10-20% of T-cell ALLs 105, 106 . NT5C2 is a 5ʹ nucleotidase that c, If mutations occur in tumorigenic cells, then both clonal evolution and the differentiation of tumorigenic cells into non-tumorigenic progeny contribute to tumour heterogeneity. This is probably what occurs in cancers that follow the stem-cell model. This means that phenotypic and functional differences cannot automatically be ascribed to epigenetic differences among tumorigenic and non-tumorigenic cells as genetic heterogeneity may contribute to some of those differences.
•
• Cancer stem-cell markers will have to be tested in significant numbers of patients 15, 40, 65 to account for heterogeneity among patients and to determine whether certain markers are more reliable in certain subsets of patients. This will provide insight into whether only certain subtypes or stages of disease follow the cancer stemcell model. Studies should not assume that markers that distinguish tumorigenic from non-tumorigenic cells in one tumour will also do so in other tumours.
• • To date, there is no evidence that any combination of cancer stem-cell markers isolates any cancer stem-cell population to a high degree of purity. The inability to purify any cancer stem cell is a profound impediment to characterizing the biology of these cells with precision. Until a high degree of purity can be demonstrated, claims related to the cell-cycle distribution and gene expression profiles of 'cancer stem cells' will be of uncertain validity.
• • It will be informative to perform lineage tracing 20, 21 and selective cell ablation experiments 19 in other cancers and at other stages of disease to assess whether many, or few, cells are fated to contribute to tumour growth and disease progression.
• Studies of genetic heterogeneity should be integrated with studies of tumorigenic potential in order to develop a more realistic understanding of the extent to which individual tumorigenic cells recapitulate the heterogeneity of the tumour from which they are derived. In many cancers that follow the stem-cell model, tumorigenic cells may reproduce the cell hierarchy but not the genotype of the tumour of origin.
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can inactivate nucleoside analogues, such as the chemotherapy drugs 6-mercaptopurine and 6-thioguanine, which are used to treat ALL. The relapse-specific NT5C2 mutations are predicted to be gain-of-function mutations that enhance enzymatic activity 105, 106 . It is likely that certain genetic changes are sufficient for therapy resistance.
The intrinsic resistance of certain cancer stem cells to particular therapies combined with genetic change probably allows disease progression (Fig. 6 ). CML follows a cancer stem-cell model because CML stem cells form terminally differentiated myeloid cells during the chronic phase 107 . CML stem cells are inherently resistant to imatinib 54, [108] [109] [110] . Cells with features of CML stem cells persist after therapy, even in patients who achieve a complete cytogenetic remission 111 . Imatinib is thought to restore the health of patients with CML mainly by eliminating differentiated CML cells. This profoundly reduces the number of leukaemia cells but leaves CML stem cells lurking in the patients, ready to re-establish the disease on discontinuation of imatinib 112, 113 . As long as patients are maintained on imatinib they remain healthy, until a mutation arises in the fusion gene BCR-ABL, which confers imatinib resistance 114, 115 . In this way, the inherent imatinib resistance of CML stem cells allows the disease to smoulder in remission, but a genetic change is required if resistance to imatinib is to become more robust and the disease is to progress in the face of therapy.
Perspective
It has been suggested that the properties of cancer stem cells can explain diverse unsolved clinical problems, but in many cases these predictions have not been carefully tested (Box 1). The roles that other sources of heterogeneity (such as genetic) have in disease progression have, in many instances, not been factored into such suggestions. Moreover, difficulties verifying solid-cancer stem-cell markers have undermined efforts to confirm their existence in some cancers and to study their biology. It remains unclear to what extent these difficulties reflect variation in the expression of markers by cancer stem cells from different patients compared with the misguided efforts to apply the stem-cell model to cancers that lack hierarchical organization. The tendency not to publish data that are difficult to interpret or inconsistent with the model exaggerates the extent to which cancer stem-cell markers are conserved among patients. It is time to critically test the model and its predictions, to acknowledge when the data do not fit the model and to integrate the data with other sources of heterogeneity when they do. Tumorigenic cells are rare and phenotypically distinct in some cancers, but are common and phenotypically diverse with no clear hierarchical organization in others. We do not yet know what fraction of cancers follows the stem-cell model.
As we develop a more complete understanding of genetic heterogeneity within tumours, there may be some cancers in which genetic heterogeneity is the main driver of phenotypic and functional heterogeneity. In some cancers with pervasive genetic heterogeneity, it may not be possible to rigorously test the cancer stem-cell model as genetic differences within and between tumours could make it impossible to identify any reproducible hierarchical organization, even if there is differentiation into post-mitotic progeny. Some cancers may have epigenetic heterogeneity that is not well described by the cancer stem-cell model. Indeed, a general question concerns the extent to which the phenotypic and functional properties of cancer cells undergo reversible changes. New models of cancer heterogeneity and plasticity may emerge.
In cancers that do not follow the stem-cell model, it will be important to demonstrate this, to avoid fruitlessly focusing on small subpopulations of cancer cells that have no more capacity to drive disease progression or therapy resistance than other cancer cells. In cancers that do follow the stem-cell model, it will be important to clarify the markers that can be used to identify these cells and the contexts in which they work. It will also be crucial to integrate our understanding of the biology of these cells with our understanding of other sources of heterogeneity, to develop a realistic view of how each contributes to disease progression. 
